Skip to content

Cost Assistance and Medication Access

UnitedTherapeuticsCares logo

United Therapeutics Cares™:
United for your patients

United Therapeutics Cares is a patient support program that connects your patients with a dedicated team of specialists who provide education on access, affordability, and treatment support from day one. Our team will work one-on-one with your patients to provide ongoing, personalized support including:

  • Education & Expectations: keeping patients informed about their treatment and what’s next in their United Therapeutics treatment journey
  • Coverage & Reimbursement: initiating the benefits investigation process and setting expectations on prior authorizations, appeals, and reimbursement needs
  • Cost & Savings: education on United Therapeutics co-pay assistance and patient assistance programs
  • Prescription Coordination: oversight throughout the referral process, working directly with one of our specialty pharmacy partners to triage your prescription, confirm coverage, and monitor prescription status
  • Treatment Support: regular patient check-ins and access to Patient Education Specialists who can be an additional resource during your patient’s United Therapeutics treatment journey

Visit UnitedTherapeuticsCares.com to learn more and enroll your patient today.

Call United Therapeutics Cares at 1-844-864-8437, Monday through Friday, 8:30 am – 7 pm ET.

Co-Pay Assistance Program

Most eligible patients pay as little as a $0 co-pay for each prescription.

This program is only valid for patients with commercial (also known as private) insurance who are taking the medication for an FDA-approved indication. The program is only valid for the cost of Orenitram and not applicable to any related supplies or other medical expenses associated with administering the product.

TO ENROLL IN THIS PROGRAM, YOUR PATIENTS MUST UNDERSTAND AND AGREE TO COMPLY WITH THE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.

Orenitram 90 Day Trial Program logo

90-Day Trial Program

The 90-Day Trial Program allows you to assess how well your eligible* patients tolerate Orenitram at no cost for up to 90 days. See if they’re eligible to enroll in the program.

View Program Details >

Additional Support Resources

Specialty Pharmacy Support

Read about how Specialty Pharmacies may help your patients access Orenitram, schedule nurse visits, and much more.

UnitedTherapeuticsCares logo

United Therapeutics Cares

Discover how a dedicated United Therapeutics Cares Patient Navigator may provide your patients with ongoing, one-on-one education and support.

Video and Resource Library

To access helpful videos, downloadable resources for patients, and recent publications, visit Video and Resource Library.

*Eligibility for this program is limited to patients with PAH (WHO Group 1) who have never been treated with Orenitram. Patients transitioning from another treprostinil medication are not eligible for this program.

PAH=pulmonary arterial hypertension; WHO=World Health Organization.

IMPORTANT SAFETY INFORMATION

Contraindications

  • Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

Warnings and Precautions

  • Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
  • The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

IMPORTANT SAFETY INFORMATION

Contraindications

  • Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

Warnings and Precautions

  • Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
  • The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

Adverse Reactions

  • In the 12-week, placebo-controlled, monotherapy study, and an event-driven placebo-controlled, combination therapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, vomiting, flushing, pain in jaw, pain in extremity, hypokalemia, abdominal discomfort, and upper abdominal pain.

Drug Interactions

  • Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients.

Specific Populations

  • Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies with Orenitram in pregnant women.
  • It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
  • Safety and effectiveness of Orenitram in pediatric patients have not been established.
  • Use of Orenitram in patients aged 65 years and over demonstrated slightly higher absolute and relative adverse event rates compared to younger patients. Caution should be used when selecting a dose for geriatric patients.
  • There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients.

INDICATION

Orenitram is a prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

OREISIhcpOCT19

Please see Full Prescribing Information and Patient Information for Orenitram.

For additional information, call 1-877-UNITHER (1-877-864-8437).